Zobrazeno 1 - 10
of 236
pro vyhledávání: '"C Truffot-Pernot"'
Autor:
H. Courtois, V. Jarlier, F. Heron, F Lecomte, C. Truffot-Pernot, M. Huerre, Hervé Levesque, Isabelle Marie, A. Laquerriere
Publikováno v:
European Journal of Internal Medicine. 14:386-389
Mycobacterium fortuitum is a rapidly growing, nontuberculous mycobacteria that has rarely been associated with central nervous system impairment. We describe the case of a patient who developed multiple cerebral abscesses revealing Mycobacterium fort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f0f21b441e6ae61045add1e3464020f
https://doi.org/10.1016/s0953-6205(03)90008-2
https://doi.org/10.1016/s0953-6205(03)90008-2
Publikováno v:
Médecine et Maladies Infectieuses. 33:173-179
Resume Les travaux menes depuis un demi-siecle chez l’animal et surtout chez la souris, ont permis de jeter les bases de la chimiotherapie de la tuberculose et de mettre au point les traitements utilises aujourd’hui chez l’homme. Les modeles mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c866fb41c2e6346ac7d85f4e6599ceb8
https://doi.org/10.1016/s0399-077x(03)00066-0
https://doi.org/10.1016/s0399-077x(03)00066-0
Autor:
B. Dautzenberg, D. Sassella, D Vittecoq, P Castellani, C Truffot-Pernot, N. Pirotta, J L Pellegrin
Publikováno v:
Antimicrobial Agents and Chemotherapy. 40:1722-1725
Rifabutin, 600 mg/day, was compared with a placebo in the early treatment of culture-proven Mycobacterium avium bacteremia in patients with AIDS. Following 14 days' treatment, bacteriological success, defined as a negative culture or a reduction in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d08712b1b092f516b76f484085007f
https://doi.org/10.1128/aac.40.7.1722
https://doi.org/10.1128/aac.40.7.1722
Autor:
C. Truffot-Pernot, F. Mantoux, Jean-Philippe Lacour, K. Angeli, P. André, J.-C. Roujeau, Ortonne Jp
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 131:198-200
Resume Introduction Les infections cutanees a Mycobacterium fortuitum ( M. fortuitum ) sont rares, le plus souvent iatrogenes. Nous rapportons un cas avec atteinte cervicale survenue apres une intervention pour lifting. Observation Une femme de 65 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1477a0433e851e3d7953b399f5327ad9
https://doi.org/10.1016/s0151-9638(04)93571-5
https://doi.org/10.1016/s0151-9638(04)93571-5
Autor:
T. Lazard, Jean-Jacques Pocidalo, J Grosset, Yves Cohen, C Truffot-Pernot, Jean-Louis Vildé, C Perronne
Publikováno v:
Antimicrobial Agents and Chemotherapy. 39:735-738
Several murine models have been used to evaluate the activities of antimicrobial agents against Mycobacterium avium infection. The main model used is the beige mouse model, but beige mice are expensive and not easily available. Thus, we developed a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41075a9bf5ed5ad260885aa51c1f3a4e
https://doi.org/10.1128/aac.39.3.735
https://doi.org/10.1128/aac.39.3.735
Autor:
B. Heym, N. Honoré, C. Schurra, S.T. Cole, C. Truffot-Pernot, J.H. Grosset, A. Banerjee, W.R. Jacobs, J.D.A. van Embden
Publikováno v:
The Lancet. 344:293-298
Tuberculosis-control programmes are compromised by the increased frequency of multidrug-resistant strains of Mycobacterium tuberculosis. We used the polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) analysis technique
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025dce49e470e5aa025192ff789c10dd
https://doi.org/10.1016/s0140-6736(94)91338-2
https://doi.org/10.1016/s0140-6736(94)91338-2
Autor:
C, Truffot-Pernot, N, Veziris
Publikováno v:
Revue des maladies respiratoires. 28(8)
This review describes current developments for the bacteriological diagnosis of active tuberculosis. It deals mainly with molecular methods, describing their performance and how they can be integrated into more traditional diagnostic approaches. At p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::63b6807b9fa241ba96cce9dfe1cdcf69
https://pubmed.ncbi.nlm.nih.gov/22099409
https://pubmed.ncbi.nlm.nih.gov/22099409
Publikováno v:
Antimicrobial Agents and Chemotherapy. 36:2408-2412
Sparfloxacin (50 mg/kg of body weight given subcutaneously each day), alone or in combination with ethambutol (50 mg/kg given subcutaneously each day), was examined for its therapeutic efficacy against experimental infection induced with the Mycobact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4c114d807232263ccde06c310c3fe64
https://doi.org/10.1128/aac.36.11.2408
https://doi.org/10.1128/aac.36.11.2408
Publikováno v:
Tubercle. 72:181-186
The in vitro and in vivo activities of sparfloxacin (AT-4140) against M. tuberculosis are reported. The MICs of sparfloxacin for 50% and 90% of 18 clinical isolates were, respectively, 0.25 and 0.5 mg/l, one or two dilutions lower than that of ciprof
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::790fbaff3c9d71c11f56504e57f27885
https://doi.org/10.1016/0041-3879(91)90004-c
https://doi.org/10.1016/0041-3879(91)90004-c
Publikováno v:
Tubercle. 72:57-64
The minimal inhibitory concentrations for 90% of strains (MIC90) of ofloxacin against Mycobacterium tuberculosis and Mycobacterium xenopi was 2 mg/I. This was three dilutions lower than that of pefloxacin and was well within the range of drug concent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f831dbe192fec7152cf844bbcf0ad245
https://doi.org/10.1016/0041-3879(91)90025-n
https://doi.org/10.1016/0041-3879(91)90025-n